Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Laurence Albiges; Tom Powles; Michael Staehler; Karim Bensalah; Rachel H. Giles; Milan Hora; Markus A. Kuczyk; Thomas B. Lam; Börje Ljungberg; Lorenzo Marconi; Axel S. Merseburger; Alessandro Volpe; Yasmin Abu-Ghanem; Saeed Dabestani; Sergio Fernández-Pello; Fabian Hofmann; Teele Kuusk; Rana Tahbaz; Axel Bex

doi:10.1016/j.eururo.2019.05.022

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Laurence Albiges
, Tom Powles
, Michael Staehler
, Karim Bensalah
, Rachel H. Giles
, Milan Hora
, Markus A. Kuczyk
, Thomas B. Lam
, Börje Ljungberg
, Lorenzo Marconi
, Axel S. Merseburger
, Alessandro Volpe
, Yasmin Abu-Ghanem
, Saeed Dabestani
, Sergio Fernández-Pello
, Fabian Hofmann
, Teele Kuusk
, Rana Tahbaz
, Axel Bex

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

Lingua originale	Inglese
pagine (da-a)	151-156
Numero di pagine	6
Rivista	European Urology
Volume	76
Numero di pubblicazione	2
DOI	https://doi.org/10.1016/j.eururo.2019.05.022
Stato di pubblicazione	Pubblicato - ago 2019
Pubblicato esternamente	Sì

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Accesso al documento

10.1016/j.eururo.2019.05.022

Altri file e collegamenti

Link to publication in Scopus

Cita questo

Albiges, L., Powles, T., Staehler, M., Bensalah, K., Giles, R. H., Hora, M., Kuczyk, M. A., Lam, T. B., Ljungberg, B., Marconi, L., Merseburger, A. S., Volpe, A., Abu-Ghanem, Y., Dabestani, S., Fernández-Pello, S., Hofmann, F., Kuusk, T., Tahbaz, R., & Bex, A. (2019). Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. European Urology, 76(2), 151-156. https://doi.org/10.1016/j.eururo.2019.05.022

@article{e4462262d7724c44bebf831c1b41b5c5,

title = "Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma",

abstract = "Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment na{\"i}ve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.",

keywords = "Cabozantinib, Guidelines, Immune checkpoint inhibitors, Ipilimumab, Metastatic, Nivolumab, Pazopanib, Renal cell carcinoma, Sunitinib",

author = "Laurence Albiges and Tom Powles and Michael Staehler and Karim Bensalah and Giles, \{Rachel H.\} and Milan Hora and Kuczyk, \{Markus A.\} and Lam, \{Thomas B.\} and B{\"o}rje Ljungberg and Lorenzo Marconi and Merseburger, \{Axel S.\} and Alessandro Volpe and Yasmin Abu-Ghanem and Saeed Dabestani and Sergio Fern{\'a}ndez-Pello and Fabian Hofmann and Teele Kuusk and Rana Tahbaz and Axel Bex",

note = "Publisher Copyright: {\textcopyright} 2019 European Association of Urology",

year = "2019",

month = aug,

doi = "10.1016/j.eururo.2019.05.022",

language = "English",

volume = "76",

pages = "151--156",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "2",

}

Albiges, L, Powles, T, Staehler, M, Bensalah, K, Giles, RH, Hora, M, Kuczyk, MA, Lam, TB, Ljungberg, B, Marconi, L, Merseburger, AS, Volpe, A, Abu-Ghanem, Y, Dabestani, S, Fernández-Pello, S, Hofmann, F, Kuusk, T, Tahbaz, R & Bex, A 2019, 'Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma', European Urology, vol. 76, n. 2, pagg. 151-156. https://doi.org/10.1016/j.eururo.2019.05.022

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. / Albiges, Laurence; Powles, Tom; Staehler, Michael et al.
In: European Urology, Vol. 76, N. 2, 08.2019, pag. 151-156.

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

TY - JOUR

T1 - Updated European Association of Urology Guidelines on Renal Cell Carcinoma

T2 - Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

AU - Albiges, Laurence

AU - Powles, Tom

AU - Staehler, Michael

AU - Bensalah, Karim

AU - Giles, Rachel H.

AU - Hora, Milan

AU - Kuczyk, Markus A.

AU - Lam, Thomas B.

AU - Ljungberg, Börje

AU - Marconi, Lorenzo

AU - Merseburger, Axel S.

AU - Volpe, Alessandro

AU - Abu-Ghanem, Yasmin

AU - Dabestani, Saeed

AU - Fernández-Pello, Sergio

AU - Hofmann, Fabian

AU - Kuusk, Teele

AU - Tahbaz, Rana

AU - Bex, Axel

PY - 2019/8

Y1 - 2019/8

N2 - Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

AB - Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.

KW - Cabozantinib

KW - Guidelines

KW - Immune checkpoint inhibitors

KW - Ipilimumab

KW - Metastatic

KW - Nivolumab

KW - Pazopanib

KW - Renal cell carcinoma

KW - Sunitinib

UR - https://www.scopus.com/pages/publications/85066081578

U2 - 10.1016/j.eururo.2019.05.022

DO - 10.1016/j.eururo.2019.05.022

M3 - Article

SN - 0302-2838

VL - 76

SP - 151

EP - 156

JO - European Urology

JF - European Urology

IS - 2

ER -

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo